Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 4/20 | 0.68 |
| ▸ | HPGDS | O60760 | 2/20 | 0.56 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.54 |
| ▸ | NNMT | P40261 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | F7 | P08709 | 1/20 | 0.52 |
| ▸ | F3 | P13726 | 1/20 | 0.52 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.52 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.52 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.52 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.52 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.52 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | P4HA1 | P13674 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28173955 | 0.98 | P4HTM (0.66) | P4HTMHPGDSCHEK2NNMTSMN1; SMN2 | |
| SCHEMBL19581478 | 0.87 | NNMT (0.65) | P4HTMHPGDSNNMTSMN1; SMN2F7 | |
| Dipyridyl SCHEMBL15380517 | 0.85 | TDP1 (0.67) | P4HTMCHEK2SMN1; SMN2F7F3 | |
| SCHEMBL687378 | 0.84 | P4HTM (0.74) | P4HTMHPGDSSMN1; SMN2KDM4ELMNA | |
| SCHEMBL3408513 | 0.84 | HPGDS (0.55) | P4HTMHPGDSCHEK2NNMTSMN1; SMN2 | |
| SCHEMBL29913684 | 0.84 | P4HTM (0.74) | P4HTMHPGDSSMN1; SMN2KDM4ELMNA | |
| SCHEMBL28576114 | 0.84 | P4HTM (0.70) | P4HTMHPGDSSMN1; SMN2KDM4ELMNA | |
| Hydrochloric Acid SCHEMBL29488111 | 0.82 | P4HTM (0.71) | P4HTMHPGDSSMN1; SMN2KDM4ELMNA | |
| SCHEMBL29488117 | 0.82 | P4HTM (0.71) | P4HTMHPGDSSMN1; SMN2KDM4ELMNA | |
| Dipyridyl SCHEMBL28724644 | 0.81 | KDM4E (0.56) | P4HTMCHEK2SMN1; SMN2F7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115531554-B | Synthetic lethal nano-drug combination carrier and application thereof in preparation of GBM targeted drugs | 河南大学 | 2023-08-11 | — | — | CN | claimed |
| US-20250263407-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2025-08-21 | — | — | US | disclosed |
| US-11851428-B2 | Activator of TREK (TWIK RElated K+channels) channels | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-12-26 | — | — | US | disclosed |
| US-20210347773-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-11-11 | — | — | US | disclosed |
| US-11046683-B2 | Activator of TREK (TWIK RElated K+ channels) channels | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-29 | — | — | US | disclosed |
| US-20200339569-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2020-10-29 | — | — | US | disclosed |
| CN-110402141-A | The conjoint therapy of Axl inhibitor and EGFR tyrosine kinase inhibitor | DAIICHI SANKYO CO LTD | 2019-11-01 | — | — | CN | disclosed |
| US-20190322662-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-10-24 | — | — | US | disclosed |
| CN-105939998-B | Heteroaryl compound and application thereof as BTK inhibitor | 默克专利有限公司 | 2019-04-16 | — | — | CN | disclosed |
| CN-107209186-A | The measure of BTK inhibitor | 默克专利有限公司 | 2017-09-26 | — | — | CN | disclosed |
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| EP-1720542-A4 | ARYLALKYLAMINO-SUBSTITUTED QUINAZOLINE ANALOGUES | NEUROGEN CORP (US) | 2007-11-28 | — | — | EP | disclosed |
| EP-1720542-A1 | ARYLALKYLAMINO-SUBSTITUTED QUINAZOLINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-11-15 | — | — | EP | disclosed |
| EP-1581225-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAIN | NEUROGEN CORPORATION (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2005087227-A1 | ARYLALKYLAMINO-SUBSTITUTED QUINAZOLINE ANALOGUES | NEUROGEN CORPORATION (US) | 2005-09-22 | — | — | WO | disclosed |
| EP-1569926-A1 | CARBOXYLIC ACID, PHOSPHATE OR PHOSPHONATE SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1471910-A2 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS MODULATORS OF CAPSAICIN RECEPTORS | NEUROGEN CORPORATION (US) | 2004-11-03 | — | — | EP | disclosed |
| WO-2004055004-A1 | CARBOXYLIC ACID, PHOSPHATE OR PHOSPHONATE SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| WO-2004054582-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAIN | NEUROGEN CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| WO-2003062209-A2 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS MODULATORS OF CAPSAICIN | NEUROGEN CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339569-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITORS | HDAC6, HDAC1, HDAC3 | P4HTM 2628/4885HPGDS 1668/4885CHEK2 1702/4885 |
| US-20250263407-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | P4HTM 2315/4885HPGDS 1204/4885CHEK2 1278/4885 |
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, AIFM1 | P4HTM 4408/4885HPGDS 1340/4885CHEK2 399/4885 |
| US-11851428-B2 | Activator of TREK (TWIK RElated K+channels) channels | KCNJ11, KCNJ1, KCNJ8 | P4HTM 2204/4885HPGDS 1223/4885CHEK2 1202/4885 |
| US-20190322662-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | KCNJ11, KCNJ1, KCNJ8 | P4HTM 2204/4885HPGDS 1223/4885CHEK2 1202/4885 |
| US-11046683-B2 | Activator of TREK (TWIK RElated K+ channels) channels | KCNJ11, KCNJ1, KCNJ8 | P4HTM 2204/4885HPGDS 1223/4885CHEK2 1202/4885 |
| US-20210347773-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | KCNJ11, KCNJ1, KCNJ8 | P4HTM 2204/4885HPGDS 1223/4885CHEK2 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.